NY State To Hold Clinical Trials For Marijuana

NEW YORK: New York State is partnering with a British company to hold clinical trials for marijuana-based medication for children who have seizures that are resistant to their medicine.

An agreement was signed Sunday between Gov. Andrew Cuomo’s administration and GW Pharmaceuticals. The state Health Department and the company will develop the framework for a clinical trial for a marijuana-based drug for people under the age of 18.

It will involve Epidiolex, an investigational medication that uses cannabidiol, a marijuana extract that doesn’t get users high. It could help children with rare forms of epilepsy such as Dravet and Lennox-Gastaut syndromes.

FDA-Approved Medical Marijuana Clinical Trial Gets Underway Next Month For Kids With Epilepsy

NEW JERSEY: A nationally renowned pediatric neurologist at Saint Barnabas has gotten FDA approval to study whether a cannabis-based drug could prevent seizures in children diagnosed with severe forms of epilepsy.

The development is sure to be watched closely in New Jersey, where a number of families whose children have Dravet syndrome, a potentially deadly form of epilepsy, say they cannot obtain yet a useful form of medicinal marijuana through the state Department of Health.

The U.S. Food and Drug Administration gave Orrin Devinsky, director of the New York University and Saint Barnabas Comprehensive Epilepsy Center, Roberta Cilio of the University of California – San Francisco’s Neurology Department, and GW Pharmaceuticals of the United Kingdom permission to use the experimental drug, Epidiolex to treat 125 children with seizure disorders for whom traditional medicines have failed.Enrollment in the trial will begin next month, Devinsky said. [Read more…]

FDA Approves Clinical Trials For Cannabis-based Epilepsy Drug

DISTRICT OF COLUMBIA: The U.S.  Food and Drug Administration has approved clinical trials of a cannabis-based drug and its effects on epilepsy.  The treatment, Epidiolex, is 98 percent purified cannabidiol ( CBD ) made by GW Pharmaceuticals based out of the U.K.

There are around 60 known chemicals contained in cannabis called cannabinoids.  Tetrahydrocannabinol, also known as THC, is the main component responsible for the drug’s psychoactive nature.  CBD, however, is the second most abundant cannabinoid in the cannabis and provides medicinal benefits without the “high.” [Read more…]